Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Global Autoimmune Disease Diagnostic Market (2021 to 2027) - Featuring Abbott Laboratories, Roche Diagnostics and Siemens Healthineers Among Others - ResearchAndMarkets.com


The "Autoimmune Disease Diagnostic Market Size Global Forecast 2021-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

This report provides a detailed analysis of Autoimmune Disease Diagnostic Industry. According to this report the market will be $8.02 Billion by 2027.

Autoimmune Disease Diagnosis and Treatment Drives the Market

In autoimmune disease diagnostics, the autoantibody screening is acting as a medium to diagnose and monitor levels further to predict the progression of the disease. However, vague and slow to exhibit signs and symptoms present may mislead during analysis. Some of the more common symptoms of autoimmune disorders include fatigue, general feeling of being unwell (malaise), dizziness, joint pain, rash, and low-grade fever.

Hence, laboratory tests are performed to diagnose autoimmune disorders depending on the particular condition the health practitioner suspects a person is suffering from. Besides, tests usually include blood tests for one or more auto antibodies. Tests for inflammation include such as C-reactive protein (CRP, the preferred test) and erythrocyte sedimentation rate (ESR).

Worldwide Autoimmune Diseases Diagnostics Industry will grow with a CAGR of 8.41% during 2021 to 2027

By Type, Systemic Autoimmune Diseases and Localized Autoimmune Disease Diagnostics are two significant types of Autoimmune Disease Diagnostic. Wherein, systemic autoimmune diseases are a broad range of related diseases characterized by dysregulation of the immune system, which activates immune cells to attack autoantigens and results in inappropriate inflammation and multi-tissue damages. Moreover, vital organs such as lung and kidney involvement in systemic autoimmune diseases are common and always presented in a progressive pattern with limited treatment strategy, making them be one of the most common causes of death in patients. These diseases are frequently conducted by clinical immunology/allergy specialists and rheumatologists.

Whilst localized (organ-specific) autoimmune diseases mainly affect a single organ or tissue. The effects frequently extend to other body systems and organs. Moreover, these diseases are often managed by organ-specific medical specialists, such as endocrinologists, gastroenterologists, neurologists or rheumatologists. As per our analysis, the market shares of Localized Autoimmune Disease Diagnostics are expected to be dominant throughout the forecast period.

The Global Autoimmune Disease Diagnostics Market is classified into North America, Europe, Asia Pacific, Middle East & Africa and Latin America. As per our analysis, in Europe, the rising incidences of chronic diseases, the increasing geriatric population are the major factors spurring the autoimmune disease diagnosis industry growth, making it the most dominant in the market. Moreover, the Asia-Pacific is expected to show extensive market growth during the forecast period, owing to increasing disposable income and the growing patient pool in developing countries.

Cumulative Impact of COVID-19 on Autoimmune Disease:

Globally, the patients suffering from autoimmune disease feared the COVID-19 had severe adverse reactions or that the autoimmune condition may worsen amidst the pandemic. Consequently, these patients could be at a higher risk of severe COVID-19. Hence, the health providers working consistently for the patients promoted regular autoimmune disease diagnosis booming the industry growth.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1 Growth Drivers

4.2 Challenges

5. Global Autoimmune Disease Diagnostics Market

6. Market Share - Autoimmune Disease Diagnostics Market

6.1 By Type

6.2 By Disease

6.3 By End Users

6.4 By Region

7. Type - Autoimmune Disease Diagnostics Market

7.1 Systemic Autoimmune Disease Diagnostics

7.2 Localized Autoimmune Disease Diagnostics

8. Disease - Autoimmune Disease Diagnostics Market

8.1 Systemic Lupus Erythematosus

8.2 Thyroiditis

8.3 Rheumatoid Arthritis

8.4 Sjogren's Syndrome

8.5 Scleroderma

8.6 Others

9. End Users - Autoimmune Disease Diagnostics Market

9.1 Hospitals

9.2 Clinical Laboratories

9.3 Others

10. Region - Autoimmune Disease Diagnostics Market

10.1 North America

10.2 Europe

10.3 Asia Pacific

10.4 Middle East & Africa

10.5 Latin America

11. Porters Five Forces

11.1 Overview

11.2 Bargaining Power of Buyers

11.3 Bargaining Power of Suppliers

11.4 Degree of Competition

11.5 Threat of New Entrants

11.6 Threat of Substitutes

12. Company Analysis

12.1 Abbott Laboratories

12.1.1 Overview

12.1.2 Recent Development

12.1.3 Financial Insights

12.2 Bio-Rad Laboratories

12.2.1 Overview

12.2.2 Recent Development

12.2.3 Financial Insights

12.3 Roche Diagnostics

12.3.1 Overview

12.3.2 Recent Development

12.3.3 Financial Insights

12.4 Siemens Healthineers

12.4.1 Overview

12.4.2 Recent Development

12.4.3 Financial Insights

12.5 bioMerieux SA

12.5.1 Overview

12.5.2 Recent Development

12.5.3 Financial Insights

For more information about this report visit https://www.researchandmarkets.com/r/gwvl8s


These press releases may also interest you

at 01:00
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...

at 00:01
Celltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients...

16 mai 2024
Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million in cash,...

16 mai 2024
Seelos Therapeutics, Inc. ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system ("CNS") disorders and rare diseases, announced today that it has entered into a...

16 mai 2024
We are advised by Hidden River Eating Disorder Residential Treatment that journalists and other readers should disregard the news release, Hidden River Announces Insurance Contract with Blue Cross Blue Shield, issued 16-May-2024 over PR Newswire....

16 mai 2024
Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced the appointment of Mark S. de Jong, PhD, to the newly created position of Chief Technical Officer (CTO). Dr. de Jong, joins Full-Life with 43...



News published on and distributed by: